Introduction
Although the current treatment strategy (wait-and-watch strategy) for
type B intramural hematoma (IMHB) is in line with the management of type
B dissection, the long-term outcomes of IMHB are not as good as those of
type B dissection [1-4] . The cause of this phenomenon is
that the evolution of IMHB is highly unpredictable and can vary from
complete resolution to abrupt rupture. Schoenhoff et al.[5] reported that 43% of IMHB patients underwent thoracic
endovascular aortic repair (TEVAR) during the first two weeks because of
visualization of an entry tear and development of an aneurysm, and 19%
of patients received TEVAR after the acute phase and during the first
year. Durham and colleagues also reported that the survival
rate of IMHB patients who underwent interventional treatment was only
76%, and only 40% of patients did not require reintervention